Gary Rabin has a 25-year career in finance and operations that primarily encompasses investing in, managing and capital-raising for small-cap and emerging growth companies.
(read full bio)
Official Advanced Cell Technology, Inc social media
We are very pleased to update you on our latest progress and some significant upcoming milestones.
As you may know, we recently announced that ACT was granted EU orphan medicinal product designation for our retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) for the treatment of Stargardt’s Macular Dystrophy (SMD).
Additionally, we also announced that the first patients had been enrolled at the Jules Stein Eye Institute at UCLA for our two upcoming Phase 1/2 clinical trials using hESC-derived RPE cells for Stargardt’s disease and Dry Age-Related Macular Degeneration (Dry AMD). They are finishing the testing and pre-surgical preparations on these patients currently, and the surgeries are scheduled for the second week in July.
We hope you will continue to check in with us at this exciting time to learn more about ACT’s latest developments and our clinical progress.
Thank you.
Gary Rabin
Interim Chairman and CEO
Advanced Cell Technology, Inc.
Martina Schwarzkopf, Ph.D.
Russo Partners, LLC
(212) 845-4292
martina.schwarzkopf [at] russopartnersllc [dot] com
Investor Relations
James Young
jyoung [at] ceocast [dot] com
(212) 732-4300
The posts and opinions expressed on this site represent those of individual contributors and unless clearly labeled as such do not represent the opinions or policies of Advanced Cell Technology, Inc.
By using this site you acknowledge that Advanced Cell Technology, Inc. is providing the material for informational purposes only and that neither Advanced Cell Technology, Inc. nor their agents, affiliates, partners, or licensors are providing the materials to you for the purposes of giving you medical advice. You should not rely on the materials in deciding on a treatment plan, drug usage, or any other medical advice regarding the materials, and Advanced Cell Technology, Inc., and their licensors strongly urge that you consult with a physician in connection with any and all treatment options that may be available to you.
By using this site, you accept the information, products, and services provided herein "as is". Advanced Cell Technology, Inc. makes no express or implied warranty regarding the accuracy, content, completeness, reliability, operability, or legality of information contained within this site, including, without limitation, the warranties of merchantability, fitness for a particular purpose, and non-infringement of proprietary rights.
In no event shall Advanced Cell Technology, Inc., or its agents, affiliates, partners, or licensors be liable for any direct, special, indirect, incidental or consequential damages or any damages whatsoever resulting from loss related to the use of our sites, whether in an action of contract, breach of warranty, negligence, or other tortious action arising out of or in connection with the use of the materials contained on this site.
(No commercial advertising involvement of any kind has been solicited or accepted in the authorship of the content within a Chairman's company blog. Advertising placed on this website is not endorsed or affiliated with authors, the chairmen, CEO's, or their respective companies.)
0 Comments
Be the first to comment!
Log in or create an account to post a comment.